Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Inoviq Ltd ( (AU:IIQ) ) just unveiled an update.
INOVIQ Limited has announced significant results from its EXO-OC™ ovarian cancer test, presented at the American Society of Clinical Oncology Annual Meeting. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, with no missed early-stage diagnoses. This breakthrough positions INOVIQ as a leader in exosome technology, addressing the critical unmet need for early detection of ovarian cancer. The company plans to further develop and commercialize the test, seeking regulatory approval and aiming to launch it as a Laboratory Developed Test in the US, potentially saving lives by enabling earlier diagnosis and intervention.
More about Inoviq Ltd
INOVIQ Limited is a company specializing in exosome technology, offering diagnostic solutions aimed at transforming precision oncology. The company is focused on developing and commercializing innovative diagnostic tests, particularly in the field of cancer detection.
Average Trading Volume: 93,889
Technical Sentiment Signal: Sell
Current Market Cap: A$49.12M
Learn more about IIQ stock on TipRanks’ Stock Analysis page.